Physician profile
Marcella Mora
NPI 1699498667
$6,125.70
in general payments reported to CMS, 2019-2025
38 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $253 · 2023: $1,877 · 2024: $2,464 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,861 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,860.64 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.11 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $770.25 | 2023-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $454.60 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $422.75 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Supernus Pharmaceuticals, INC. | $324.61 | 2023-2025 | Qelbree, Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.84 | 2022-2025 | Cycloset, Xifaxan |
| Amgen INC. | $286.96 | 2023-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $272.21 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $265.49 | 2023-2025 | Abilify Asimtufii, Vyepti, Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $259.18 | 2022-2025 | |
| Axsome Therapeutics, INC. | $234.66 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $203.25 | 2023-2024 | Xarelto, Invega Sustenna |
| Merck Sharp & Dohme LLC | $162.81 | 2023-2025 | Verquvo, Belsomra, Steglatro |
| Azurity Pharmaceuticals, INC. | $160.53 | 2023-2025 | Horizant, Horizant, Edarbi |
| Becton, Dickinson and Company | $109.19 | 2025 | Phasix Mesh |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $103.15 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $98.74 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $98.31 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $97.56 | 2024-2025 | Fanapt, Hetlioz |
| Shield Therapeutics INC | $69.74 | 2024 | |
| Sumitomo Pharma America, INC. | $62.38 | 2023-2025 | Gemtesa |
| Neurocrine Biosciences, INC. | $55.06 | 2023-2025 | Ingrezza |
| Esperion Therapeutics, INC. | $50.94 | 2023-2024 | Nexletol |
| Almatica Pharma LLC | $50.09 | 2024 | Loreev Xr |
| Aimmune Therapeutics, INC. | $49.19 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $45.50 | 2023-2024 | Austedo Xr |
| Aprecia Pharmaceuticals, LLC | $31.75 | 2022-2023 | Spritam |
| Scilex Pharmaceuticals INC. | $29.59 | 2022 | |
| Currax Pharmaceuticals LLC | $28.83 | 2022 | |
| Alk-Abello, INC | $25.29 | 2025 | Ragwitek, Grastek, Odactra |
| Exact Sciences Corporation | $23.82 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $20.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.74 | 2023 | Ofev |
| Dexcom, INC. | $17.05 | 2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $16.72 | 2023 | Afrezza |
| Novo Nordisk INC | $15.68 | 2023 | Ozempic, Rybelsus |
| Averitas Pharma INC. | $13.91 | 2025 | Qutenza |
| Ironshore Pharmaceuticals INC. | $12.86 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcella Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.